ReviewInternational journal of molecular sciences2026
Beyond the Classical View: Early Emergence of Class Switch Recombination-Associated Molecular Features During B-Cell Development in the Bone Marrow.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Class switch recombination (CSR) is a fundamental mechanism of humoral immunity that enables activated B lymphocytes to switch from the expression of IgM to other immunoglobulin isotypes, such as IgG, IgA, or IgE, thereby changing the effector functions while preserving antigen specificity. Traditionally, CSR has been considered a late event in B-cell differentiation, occurring predominantly in germinal centers following antigen encounter and activation-induced cytidine deaminase (AID) expression. In this classical model, B-cell development in the bone marrow is largely separated from antigen-dependent antibody diversification in peripheral lymphoid organs. However, transcriptomic, epigenomic, and functional studies suggest that several molecular components and regulatory features associated with CSR may already emerge during early stages of B-cell ontogeny. Evidence from mouse models and molecular studies indicates that immature and transitional B cells can express low levels of AID, while transcriptional and regulatory features linked to CSR may already be established before antigen-driven B-cell activation. In this review, we first summarize the classical process of CSR, including the molecular events and requirements necessary for its activation in mature B cells. We then discuss evidence indicating that components and regulatory features associated with CSR can emerge during early B-cell development. Furthermore, we examine how transcriptional regulation and enhancer activity within the IgH locus may contribute to the establishment of these features throughout ontogeny. Finally, we discuss the potential biological implications of early CSR-associated molecular activity for immune repertoire formation, central tolerance, genomic integrity, and B-cell malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.